Dayra Therapeutics Raises Over $70M in Funding From Biogen and Versant Ventures

Why It Matters

The capital infusion validates the commercial potential of oral macrocyclic peptides and gives Dayra the resources to advance its pipeline, while Biogen’s involvement signals major pharma interest in novel peptide therapeutics, potentially reshaping treatment options in high‑unmet‑need areas.

Key Takeaways

• $50M upfront from Biogen collaboration
• Additional $20M+ equity from Versant Ventures
• Focus on oral macrocyclic peptide therapeutics
• Originated from Versant’s Frontier Discovery Engine

Pulse Analysis

Oral macrocyclic peptides are emerging as a disruptive class of therapeutics, offering the potency of biologics with the convenience of small‑molecule drugs. Traditional peptide drugs suffer from poor stability and low bioavailability, but macrocyclization can dramatically improve these properties. Dayra’s platform leverages advanced chemistry and computational design to create orally deliverable candidates, positioning the company at the forefront of a market projected to exceed $10 billion within the next decade.

The $70 million financing package underscores the strategic value of Dayra’s technology. Biogen’s $50 million upfront commitment not only provides critical runway but also establishes a collaborative framework for co‑development, potentially accelerating the transition of Dayra’s lead programs into late‑stage trials. Versant Ventures’ equity stake adds further validation from a venture capital firm known for backing high‑impact biotech ventures, reinforcing confidence in the company’s scientific and commercial prospects.

Beyond Dayra, this deal reflects a broader shift in biotech financing toward specialty platforms that address delivery challenges. Investors are increasingly allocating capital to companies that can bridge the gap between biologic efficacy and oral administration, a sweet spot for chronic disease treatment. As more pharma partners seek to diversify their pipelines with innovative peptide modalities, Dayra’s funding milestone may catalyze additional collaborations, driving competitive pressure and accelerating innovation across the oral peptide space.

Deal Summary

Dayra Therapeutics announced it has secured more than $70 million in committed funding, including a $50 million upfront collaboration with Biogen Inc. and an equity commitment from Versant Ventures. The capital will support the development of oral macrocyclic peptide therapies for serious diseases.